NLS Pharmaceutics Announces Compliance With Nasdaq Bid Price Requirement
NLS Pharmaceutics Announces Compliance With Nasdaq Bid Price Requirement
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.
瑞士苏黎世/ACCESSWIRE/2023年1月12日/瑞士临床阶段生物制药公司NLS制药有限公司(纳斯达克股票代码：NLSP，NLSPW)(以下简称“公司”)今天宣布，它收到了纳斯达克上市资格人员的通知函，通知公司它已重新遵守纳斯达克的最低投标价格要求。纳斯达克是一家专注于为罕见和复杂的中枢神经系统疾病患者发现和开发创新疗法的公司。
On June 10, 2022, NLS was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given a 180-day extension, or until December 5, 2022 to regain compliance. On December 6, 2022, NLS received an additional written notice from the Nasdaq Staff that the bid price requirement was not met, that NLS was not eligible for a second 180-day extension and that the bid price issue provided a separate basis for delisting of the Company's common shares.
2022年6月10日，纳斯达克首次通知NLS，其未能根据纳斯达克上市规则第5550(A)(2)和5810(C)(3)(A)条连续30个工作日维持每股1.00美元的最低收购价格，并被给予180天的延期，即至2022年12月5日，以重新获得合规。2022年12月6日，NLS收到纳斯达克工作人员的额外书面通知，称NLS未达到投标价格要求，没有资格第二次延期180天，并且投标价格问题为本公司普通股退市提供了单独的基础。
The letter NLS received from Nasdaq on January 10, 2023 noted that as of January 9, 2023, the Company evidenced a closing bid price of its common shares at or greater than the $1.00 per share minimum requirement for the last 10 consecutive business days, from December 20, 2022 through January 9, 2023. Nasdaq stated that accordingly, NLS has regained compliance with Nasdaq Listing Rule 5550(a)(2).
2023年1月10日收到的纳斯达克的信件指出，截至2023年1月9日，该公司证明其普通股的收盘价在2022年12月20日至2023年1月9日的最后10个工作日的每股最低要求为1.00美元或更高。纳斯达克表示，据此，免入息税已恢复遵守纳斯达克上市规则第5550(A)(2)条。
About NLS Pharmaceutics Ltd.
关于NLS制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS制药有限公司(纳斯达克代码：NLSP)是一家全球开发期生物制药公司，与世界级合作伙伴和国际公认的科学家网络合作，专注于为患有罕见和复杂的中枢神经系统疾病的患者发现和开发创新疗法，这些患者的医疗需求尚未得到满足。NLS总部设在瑞士，成立于2015年，由一支经验丰富的管理团队领导，该团队在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
有关更多信息，请访问：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
Marianne Lambertson(投资者和媒体)
NLS制药有限公司。
+1 239.682.8500
邮箱：ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
资料来源：NLS制药公司